Description: Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Home Page: www.omeros.com
The Omeros Building
Seattle,
WA
98119
United States
Phone:
206 676 5000
Officers
| Name | Title |
|---|---|
| Dr. Gregory A. Demopulos M.D. | Co-Founder, Chairman, CEO & President |
| Mr. Peter B. Cancelmo J.D. | VP, General Counsel & Corporate Secretary |
| Dr. Pamela Pierce Palmer M.D., Ph.D. | Co-Founder |
| Mr. David J. Borges | VP of Finance, Chief Accounting Officer & Treasurer |
| Dr. George A. Gaitanaris M.D., Ph.D. | Chief Scientific Officer & VP of Science |
| Mr. Peter W. Williams | Vice President of Human Resources |
| Dr. Catherine A. Melfi Ph.D. | Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems |
| Ms. Nadia Dac | VP & Chief Commercial Officer |
| Dr. Andreas Grauer M.D. | VP & Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.2301 |
| Price-to-Sales TTM: | 4.8205 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 198 |